Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,275.00
2,551.00
-276.00
-10.82%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,275.00
2,551.00
-276.00
-10.82%
Expenditure (Ex Depriciation)
Stock Adjustments
-488.00
3.00
-491.00
-16,366.67%
Raw Materials Consumed
1,868.00
1,063.00
805.00
75.73%
Power & Fuel Cost
2.00
113.00
-111.00
-98.23%
Employee Cost
264.00
272.00
-8.00
-2.94%
Operating Expenses
20.00
173.00
-153.00
-88.44%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
124.00
56.00
68.00
121.43%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
31.00
39.00
-8.00
-20.51%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,013.00
1,754.00
259.00
14.77%
Operating Profit (PBDIT) excl Other Income
262.00
797.00
-535.00
-67.13%
Other Income
28.00
60.00
-32.00
-53.33%
Operating Profit (PBDIT)
290.00
857.00
-567.00
-66.16%
Interest
4.00
5.00
-1.00
-20.00%
Profit before Depriciation and Tax
286.00
852.00
-566.00
-66.43%
Depreciation
28.00
75.00
-47.00
-62.67%
Profit Before Taxation & Exceptional Items
257.00
776.00
-519.00
-66.88%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
252.00
751.00
-499.00
-66.44%
Provision for Tax
64.00
186.00
-122.00
-65.59%
Profit After Tax
187.00
564.00
-377.00
-66.84%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
632.00
1,777.00
-1,145.00
-64.43%
Profit Available for appropriations
820.00
2,341.00
-1,521.00
-64.97%
Appropriations
820.00
2,341.00
-1,521.00
-64.97%
Equity Dividend (%)
1800%
250%
1,550.00
Earnings Per Share
75.01
45.99
29.02
63.10%
Profit And Loss - Net Sales
Net Sales 2,275.58 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 262.03 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Profit And Loss - Interest
Interest 4.49 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax 187.52 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
Footer loading
